In contrast, combined administration of Aplidin and Dex or Aplidin and Btz significantly decreased tumor burden, demonstrating that Dex and Btz exhibit additive effects with Aplidin, enhancing its anti-MM properties (Figure 6C). Here, CASC3 is linked to neoplasm.